TP53 and acute myeloid leukemia: The adverse AML group comprises AMLs with complex karyotype, inv(3)(q21q26)/t(3;3)(q21;q26), DEK-NUP214 t(6;9)(p23;q34), RPN1-EVI1, BCR-ABL1 t(9;22)(q34.1;q11.2), KATA6-CREBBP t(8;16)(p11.2;p13.3), t(6;11), −5 or del(5q), −7 or abnormal (17p) or monosomal karyotype, TP53 mutations, RUNX1, ASXL1, BCOR, EZH2, SF3B1, STAG2, U2AF1, and ZRS2 mutations [2].